Standard BioTools Inc. (LAB)
Company Description
Standard BioTools Inc., together with its subsidiaries, creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide.
It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology.
The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.
In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays.
Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions.
It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations.
It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022.
Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 1999 |
| IPO Date | Feb 10, 2011 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 523 |
| CEO | Dr. Michael Egholm Ph.D. |
Contact Details
Address: 2 Tower Place, Suite 2000 South San Francisco, California 94080 United States | |
| Phone | (650) 266-6000 |
| Website | fluidigm.com |
Stock Details
| Ticker Symbol | LAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001162194 |
| CUSIP Number | 34385P108 |
| ISIN Number | US34385P1084 |
| Employer ID | 77-0513190 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Vikram Jog | Chief Financial Officer |
| Dr. Michael Egholm Ph.D. | President, Chief Executive Officer and Director |
| Dr. Stephen R. Quake D.phil., Ph.D. | Co-Founder and Chairman of Advisory Board |
| Hanjoon Kim | Chief Operating Officer |
| Andrew Quong Ph.D. | Chief Science Officer |
| Peter DeNardo | Investor Relations |
| Rafael Aguirre-Sacasa | Acting General Counsel |
| Mark Spearman | Senior Director of Corporate Communications |
| Angela Peters | Chief Human Resources Officer |
| Dr. David A. King Ph.D. | Senior Vice President of Global Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 23, 2023 | 144 | Filing |
| Aug 17, 2023 | 144 | Filing |
| Aug 11, 2023 | 144 | Filing |
| Aug 8, 2023 | 10-Q | Quarterly Report |
| Aug 8, 2023 | 8-K | Current Report |
| Jul 28, 2023 | 8-K | Current Report |
| Jul 7, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Jul 3, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jun 20, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 16, 2023 | 8-K | Current Report |